Spitz nevi and Spitzoid melanomas: exome sequencing and comparison with conventional melanocytic nevi and melanomas.
Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells.
RASopathy Gene Mutations in Melanoma.
Germline MC1R status influences somatic mutation burden in melanoma.
Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.
Rare SF3B1 R625 mutations in cutaneous melanoma.
Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors.
Type II p21-activated kinases (PAKs) are regulated by an autoinhibitory pseudosubstrate.
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma.
MicroRNA signatures differentiate melanoma subtypes.
Phosphoproteomic screen identifies potential therapeutic targets in melanoma.
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells.
Genome-wide methylation and expression profiling identifies promoter characteristics affecting demethylation-induced gene up-regulation in melanoma.
Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications.
MEDME: an experimental and analytical methodology for the estimation of DNA methylation levels based on microarray derived MeDIP-enrichment.